Consolidation in the emerging field of healthcare AI is inevitable. Last week's acquisition of ...

Consolidation in the emerging field of healthcare AI is inevitable. Last week's acquisition of Paige AI by Tempus AI is therefore not a surprising story. What shocked many is the deal price.

Quite often these terms are not disclosed. Here it was publicly shared that Paige was sold for only $81M. This after having raised more than $260M from top-notch investors like Goldman Sachs and JNJ Innovation. If I remember correctly, the series C was valued at $600M. OK, that was 2021, and we all know these times are over. But I must admit the current valuation is still a rather sad outcome for what was a very promising story.

Maybe this is just the reality of the market right now. Building a great product is one thing, but figuring out how to make money from it has always been a whole different beast. It seems the market is now punishing companies that haven't quite cracked that part of the code yet, even if they're technically brilliant.

Why do you think this deal was valued so low?

Source: Fierce Biotech